Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Diabetes Mellitus, Dyslipidemia, Hypercholesterolemia, Cardiovascular Disease
Interventions: Decision Aid Statin Choice; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metabolic Syndrome
Interventions: 3-V Bioscience-2640; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 35 Years to 60 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Obesity, Hypertension, Hyperlipidemia, Depression
Interventions: Self-care CVD risk reduction, Referral to primary care provider for CVD risk management; Behavioral · Other
Lead sponsor: Debra Moser; Other
Eligibility: 21 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hyperlipidemia
Interventions: MCT oil + Butter in Coffee; Dietary Supplement
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Cardiovascular Risk Factor, Hyperlipidemia
Interventions: Not listed
Lead sponsor: Susan Smyth; Other
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Coronary Artery Disease, Peripheral Arterial Disease, Hyperlipidemia, Hypertension, Diabetes, Prediabetes, Obesity
Interventions: Prevention Consult, Consult & Behavioral Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 99 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Familial Hypercholesterolemia
Interventions: Genetic testing; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Lancaster, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Insulin Resistance, Hypertriglyceridemia, Diabetes, Hepatic Steatosis
Interventions: low-fat diet ( Still recruiting ), Diet; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypercholesterolemia
Interventions: CAT-2054, Placebo, Atorvastatin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Muscle Shoals, Alabama • Huntington Park, California • Lomita, California + 28 more

Conditions: Cardiovascular Disease
Interventions: GSK2212836; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypercholesterolemia
Interventions: MD-0727; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more

Conditions: Hypertension, Hyperlipidemia
Interventions: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases, Pharmacists, Placebo Effect
Interventions: Virtual Statin Management (VSM); Other
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 80 Years
Enrollment: 898 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes Mellitus, Healthy, Hypercholesterolemia, Hypertension
Interventions: hemoglobin-transported nitric oxide; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Drug Induced Hyperglycemia, Secondary Hyperlipidemia
Interventions: Oral Glucose Tolerance Test; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Severe Hypertriglyceridemia
Interventions: Pegozafermin, Placebo; Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 32
States / cities: La Mesa, California • San Francisco, California • Clearwater, Florida + 26 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Placebo to Evolocumab, Ezetimibe, Placebo to Ezetimibe; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 20
States / cities: Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypercholesterolemia
Interventions: alirocumab SAR236553 (REGN727); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: HIV Infections, Hypercholesterolemia, Glucose Intolerance
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions: Comparison of dietary protein amino acid profile; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: Not listed
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions: Comparison of cooking oils; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Improving Heart Health in Appalachia

Effect of Butter & MCT Oil on Lipoproteins - A RCT

Dietary Sources of Lysophospholipids

Prevention Trial to Achieve Cardiovascular Targets

IN-TANDEM Familial Hypercholesterolemia Pilot Study

Novel Therapies for Metabolic Complications of Lipodystrophies

A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

The SCCS Polypill Pilot Trial

A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.

Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Impact of LDL-cholesterol Lowering on Platelet Activation

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Metabolic Abnormalities in HIV Infected and Uninfected Young Women

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients

Effect of Vegetable Oils for Use by the Snack Food Industry on Plasma Lipid Levels and Inflammatory Markers